FEG
TGTX icon

Financial Enhancement Group’s TG Therapeutics TGTX Stock Holding History

Financial Enhancement Group’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-68,480
Closed -$1.33M – 281
2020
Q2 		$1.33M Buy
+68,480
New +$1.1M 0.34% 49

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Financial Enhancement Group's TGTX Position: Q3 2020 in Review

Financial Enhancement Group sold out of TG Therapeutics (TGTX) in Q3 2020, closing a stake of 68,480 shares — an estimated $1.33M sold.

Financial Enhancement Group first reported a position in TGTX in Q2 2020 and held it in 1 quarter. The position peaked at $1.33M in Q2 2020. 181 funds tracked by Wall St. Rank hold TGTX as of Q3 2020.

  • Financial Enhancement Group reported no remaining TG Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Financial Enhancement Group sold 68,480 TG Therapeutics shares in Q3 2020, an estimated $1.33M.
  • Financial Enhancement Group first reported a position in TG Therapeutics in Q2 2020 and held it in 1 quarter.
  • Financial Enhancement Group's TG Therapeutics position peaked at $1.33M in Q2 2020.
  • 181 funds tracked by Wall St. Rank held TG Therapeutics as of Q3 2020.

Based on Financial Enhancement Group's 13F filing for Q3 2020, filed 18 Nov 2020.